Targeting Tumor Cells with Antibodies Enhances Anti-Tumor Immunity
A special issue of Antibodies (ISSN 2073-4468). This special issue belongs to the section "Antibody-Based Therapeutics".
Deadline for manuscript submissions: closed (20 November 2022) | Viewed by 5417
Special Issue Editor
Special Issue Information
Dear Colleagues,
In recent years, anti-tumor antibodies account for half of the approved antibody drugs in the world. With the research and development of new antibody drugs, and the continuous expansion of the indications of listed antibody drugs in the field of cancer, the market growth of anti-tumor antibody drugs is obvious. However, the antibody drugs that target tumor cells with antibodies to enhance anti-tumor immunotherapy are still severely insufficient. Currently, only PD-1/PD-L1 and CTLA-4 antibodies were applied in clinical treatment. However, in fact, only 20–30% of patients benefit from this immunotherapy, so it is urgent to find new targets and therapeutic antibodies to enhance tumor immunotherapy. This Special Issue aims to publish the research findings of antibodies enhancing tumor immunotherapy drugs and novel strategies related to enhancing tumor immune antibodies, and promote the research and development of anti-tumor immune antibody drugs.
Prof. Dr. Xiaoyan Qiu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anti-tumor antibodies
- tumor targets
- tumor antigen
- tumor immunotherapy
- monoclonal antibodies
- therapeutic antibodies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
